Table 1:

Development of Partially Curative Ciprofloxacin Regimen: Study Design

Group	Number of Animals (M/F)	Treatment	Dose (mg/kg)	Treatment Schedule	Blood Collection Schedule (Days)

Iteration 1

1	4/4	Saline	--	14 days TID starting 20–24 h post-challenge¹	7, 13², 34³, terminal⁴
2	10/10	Ciprofloxacin	10	14 days TID starting 20–24 h post-challenge¹	7, 13², 34³, terminal⁴

Iteration 2

1	4/4	Saline	--	14 days TID starting 20–24 h post-challenge	7, 13, 34, terminal
2	10/10	Ciprofloxacin	10	14 days TID starting 20–24 h post-challenge	7, 13, 34, terminal

Iteration 3

1	8/7	Ciprofloxacin	5	14 days TID starting 20–24 h post-challenge	7, 13, 34, terminal
2	7/8	Ciprofloxacin	7.5	14 days TID starting 20–24 h post-challenge	7, 13, 34, terminal

Iteration 4

1	8/8	Ciprofloxacin	5	14 days TID starting 20–24 h post-challenge	7, 13, 34, terminal
2	8/8	Ciprofloxacin	7.5	14 days TID starting 20–24 h post-challenge	7, 13, 34, terminal

TID = three times per day; M = male; F = female

Animals were challenged on study day 0 at time 0 with a target dose of 200 LD₅₀ of aerosolized B. anthracis spores

30 minutes (± 15 min) after the first ciprofloxacin treatment of the day

8 hours (± 1 h) after the last ciprofloxacin treatment

⁴

Terminal blood collection, if possible, on study day 34 or from any animal found dead or euthanized due to moribund condition